Voluntary nationwide recall: Vancomycin (Amneal - March)
Apr. 2024Pharmacy Updates
Amneal Pharmaceuticals, LLC is recalling four lots of Vancomycin Hydrochloride for Oral Solution, USP, 250 mg/5 mL. Vancomycin is used for treatment of certain bacterial infections.
This drug is being recalled because some bottles may have been overfilled. This may cause a higher dose to be received and may increase adverse effects, such as kidney damage.
As of the date of Amneal’s recall announcement, March 27, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Vancomycin, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
This drug is being recalled because some bottles may have been overfilled. This may cause a higher dose to be received and may increase adverse effects, such as kidney damage.
As of the date of Amneal’s recall announcement, March 27, 2024, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.
If you have an affected lot of Vancomycin, you should stop using the item and return it to the place of purchase.
To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Call Amneal at 1-833-582-0812. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
- Visit the FDA website.
Recent Announcements
CME Webinar Series: Introducing Physicians and their teams to Value-Based Health Care
Please join us for a new CME-accredited webinar series on value-based care. This series is designed to introduce practicing physicians and their teams to value-based health care. Over the course of six sessions, we will define the components of value and identify the tools necessary to deliver high-value care for a population.Feb. 2026Education/Webinars
Bridging Smiles and Systems: Collaborative Care for Children with Chronic Conditions
Please join us for a live, CME-accredited and CEU-accredited webinar on May 13 from noon to 1p.m., that will explore the critical connection between oral health and pediatric chronic conditions such as diabetes, asthma, congenital heart disease, and ADHD.Feb. 2026Education/Webinars
February 2026 UPMC for You and UPMC Community HealthChoices formulary update
Pulmicort Flexhaler has a new distributor, Rubicon Holding. National Drug Codes (NDCs) for Pulmicort Flexhaler from Rubicon Holding are not included in the Medicaid Drug Rebate program and are not covered under the Medicaid Prescription Drug Program. Pulmicort Flexhaler NDCs from the previous manufacturer, H2 Pharma, have been discontinued but may be billed/dispensed until supplies are exhausted.Feb. 2026Pharmacy Updates